FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4321429561> ?p ?o ?g. }

• W4321429561 endingPage "1370" @default.
• W4321429561 startingPage "1359" @default.
• W4321429561 abstract "BACKGROUND The role of chemotherapy in the treatment of patients with primary central nervous system lymphoma (PCL) remains unclear, with no randomized trials available to aid in the interpretation of the current data. The Medical Research Council therefore conducted the current randomized trial to assess the impact on survival of postradiotherapy chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in nonimmunocompromised adult patients with pathologically proven PCL. METHODS After surgery, patients were randomized at a ratio of 1:2 to radiotherapy alone (RT: 40 grays [Gy] in 20 fractions to the whole brain followed by a 14-Gy boost to the tumor plus a 2-cm tumor margin) or to the same radiotherapy followed by six cycles of CHOP chemotherapy given at 3-week intervals (RT-CHOP). The target sample size was 90 patients, which allowed 90% power to detect a doubling of the median survival time. RESULTS Between 1988 and 1995, 53 patients were randomized: Fifteen patients were randomized to RT, and 38 patients were randomized to RT-CHOP. The trial closed earlier than planned through poor accrual. The median patient age was 57 years, 57% of the patients were male, and 75% of the patients had unifocal disease. The median number of chemotherapy cycles received was 6 (mean, 4 cycles). Forty-three patients have died, and the median follow-up of survivors is 5 years (range, 1–9 years). There was no evidence of a benefit from RT-CHOP with respect to overall survival (hazard ratio [HR], 1.19; 95% confidence interval, 0.51–2.76) after adjustment for prognostic factors (patient age and neurologic performance status) in an analysis in which HR > 1 favored the control (RT) group. CONCLUSIONS CHOP has no clear role in the postradiotherapy treatment of patients with PCL. Chemotherapy is poorly tolerated and largely palliative in older, less fit patients. In younger patients, initial chemotherapy designed to penetrate the blood-brain barrier warrants further investigation. Cancer 2000;89:1359–70. © 2000 American Cancer Society." @default.
• W4321429561 created "2023-02-22" @default.
• W4321429561 creator A5012877366 @default.
• W4321429561 creator A5023188445 @default.
• W4321429561 creator A5040028722 @default.
• W4321429561 creator A5041038669 @default.
• W4321429561 creator A5041647637 @default.
• W4321429561 creator A5045198315 @default.
• W4321429561 creator A5045627715 @default.
• W4321429561 creator A5046287476 @default.
• W4321429561 creator A5047879448 @default.
• W4321429561 creator A5064698472 @default.
• W4321429561 creator A5065546490 @default.
• W4321429561 creator A5066576612 @default.
• W4321429561 creator A5085710622 @default.
• W4321429561 creator A5091478193 @default.
• W4321429561 date "2000-09-15" @default.
• W4321429561 modified "2023-10-16" @default.
• W4321429561 title "A medical research council randomized trial in patients with primary cerebral non-Hodgkin lymphoma" @default.
• W4321429561 cites W1480166232 @default.
• W4321429561 cites W173609426 @default.
• W4321429561 cites W1860711823 @default.
• W4321429561 cites W1874251062 @default.
• W4321429561 cites W1946301794 @default.
• W4321429561 cites W1969695259 @default.
• W4321429561 cites W1984374206 @default.
• W4321429561 cites W1985027375 @default.
• W4321429561 cites W1988295204 @default.
• W4321429561 cites W1992894038 @default.
• W4321429561 cites W1997865358 @default.
• W4321429561 cites W2045159650 @default.
• W4321429561 cites W2059619097 @default.
• W4321429561 cites W2062968968 @default.
• W4321429561 cites W2073151455 @default.
• W4321429561 cites W2079621758 @default.
• W4321429561 cites W2082804426 @default.
• W4321429561 cites W2087824134 @default.
• W4321429561 cites W2112867037 @default.
• W4321429561 cites W2113924534 @default.
• W4321429561 cites W2122090895 @default.
• W4321429561 cites W2142855102 @default.
• W4321429561 cites W2159708587 @default.
• W4321429561 cites W2179658416 @default.
• W4321429561 cites W2186111039 @default.
• W4321429561 cites W2202266713 @default.
• W4321429561 cites W4230208395 @default.
• W4321429561 cites W4247034125 @default.
• W4321429561 doi "https://doi.org/10.1002/1097-0142(20000915)89:6<1359::aid-cncr21>3.0.co;2-9" @default.
• W4321429561 hasPublicationYear "2000" @default.
• W4321429561 type Work @default.
• W4321429561 citedByCount "137" @default.
• W4321429561 countsByYear W43214295612012 @default.
• W4321429561 countsByYear W43214295612013 @default.
• W4321429561 countsByYear W43214295612014 @default.
• W4321429561 countsByYear W43214295612015 @default.
• W4321429561 countsByYear W43214295612016 @default.
• W4321429561 countsByYear W43214295612017 @default.
• W4321429561 countsByYear W43214295612018 @default.
• W4321429561 countsByYear W43214295612019 @default.
• W4321429561 countsByYear W43214295612020 @default.
• W4321429561 countsByYear W43214295612021 @default.
• W4321429561 countsByYear W43214295612022 @default.
• W4321429561 countsByYear W43214295612023 @default.
• W4321429561 crossrefType "journal-article" @default.
• W4321429561 hasAuthorship W4321429561A5012877366 @default.
• W4321429561 hasAuthorship W4321429561A5023188445 @default.
• W4321429561 hasAuthorship W4321429561A5040028722 @default.
• W4321429561 hasAuthorship W4321429561A5041038669 @default.
• W4321429561 hasAuthorship W4321429561A5041647637 @default.
• W4321429561 hasAuthorship W4321429561A5045198315 @default.
• W4321429561 hasAuthorship W4321429561A5045627715 @default.
• W4321429561 hasAuthorship W4321429561A5046287476 @default.
• W4321429561 hasAuthorship W4321429561A5047879448 @default.
• W4321429561 hasAuthorship W4321429561A5064698472 @default.
• W4321429561 hasAuthorship W4321429561A5065546490 @default.
• W4321429561 hasAuthorship W4321429561A5066576612 @default.
• W4321429561 hasAuthorship W4321429561A5085710622 @default.
• W4321429561 hasAuthorship W4321429561A5091478193 @default.
• W4321429561 hasConcept C126322002 @default.
• W4321429561 hasConcept C141071460 @default.
• W4321429561 hasConcept C168563851 @default.
• W4321429561 hasConcept C207103383 @default.
• W4321429561 hasConcept C2776694085 @default.
• W4321429561 hasConcept C2776755627 @default.
• W4321429561 hasConcept C2778720950 @default.
• W4321429561 hasConcept C2779429289 @default.
• W4321429561 hasConcept C2779725641 @default.
• W4321429561 hasConcept C44249647 @default.
• W4321429561 hasConcept C509974204 @default.
• W4321429561 hasConcept C71924100 @default.
• W4321429561 hasConceptScore W4321429561C126322002 @default.
• W4321429561 hasConceptScore W4321429561C141071460 @default.
• W4321429561 hasConceptScore W4321429561C168563851 @default.
• W4321429561 hasConceptScore W4321429561C207103383 @default.
• W4321429561 hasConceptScore W4321429561C2776694085 @default.
• W4321429561 hasConceptScore W4321429561C2776755627 @default.
• W4321429561 hasConceptScore W4321429561C2778720950 @default.
• W4321429561 hasConceptScore W4321429561C2779429289 @default.

• next